全文获取类型
收费全文 | 232篇 |
免费 | 5篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 8篇 |
妇产科学 | 2篇 |
基础医学 | 14篇 |
口腔科学 | 6篇 |
临床医学 | 11篇 |
内科学 | 93篇 |
皮肤病学 | 1篇 |
神经病学 | 7篇 |
特种医学 | 42篇 |
外科学 | 4篇 |
综合类 | 2篇 |
预防医学 | 4篇 |
药学 | 39篇 |
肿瘤学 | 5篇 |
出版年
2023年 | 2篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2017年 | 1篇 |
2015年 | 3篇 |
2014年 | 3篇 |
2013年 | 8篇 |
2012年 | 5篇 |
2011年 | 5篇 |
2010年 | 3篇 |
2009年 | 7篇 |
2008年 | 1篇 |
2007年 | 7篇 |
2006年 | 5篇 |
2005年 | 5篇 |
2004年 | 5篇 |
2003年 | 4篇 |
2002年 | 5篇 |
2001年 | 3篇 |
2000年 | 10篇 |
1999年 | 3篇 |
1998年 | 15篇 |
1997年 | 10篇 |
1996年 | 7篇 |
1995年 | 11篇 |
1994年 | 14篇 |
1993年 | 21篇 |
1992年 | 4篇 |
1991年 | 2篇 |
1989年 | 6篇 |
1988年 | 14篇 |
1987年 | 11篇 |
1986年 | 5篇 |
1985年 | 6篇 |
1984年 | 2篇 |
1983年 | 4篇 |
1982年 | 6篇 |
1981年 | 3篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1976年 | 3篇 |
1975年 | 1篇 |
排序方式: 共有238条查询结果,搜索用时 31 毫秒
41.
42.
DiFrancesco R Fischl MA Donnelly J Zingman BS McCance-Katz EF Moody DE Reichman RC Gripshover B Morse GD 《Journal of pharmaceutical and biomedical analysis》2007,44(1):188-195
The availability of buprenorphine (BUP) provides an alternative approach to the treatment of opioid addiction with methadone, an agent that has many drug-drug interactions when combined with antiretroviral therapy (ART). However, due to limited long-term pharmacokinetic studies in HIV-infected patients, the clinical use of BUP, a CYP450-3A4 substrate, will require that studies be conducted to examine safety, tolerability and pharmacokinetics when these drugs are taken for chronic treatment. One clinical approach could include plasma concentration monitoring to avoid under- or overdosing BUP secondary to drug interactions with ART. The measurement of BUP and its active metabolite, norbuprenorphine (NBUP) facilitates the addition of BUP to ART in an attempt to avoid drug toxicity as described in a recent report by Bruce et al. Therefore, our objective was to validate a BUP assay and integrate its application into an ongoing antiretroviral (ARV) plasma concentration monitoring program. A chromatographic method for monitoring BUP and its active metabolite, NBUP was investigated. An assay was developed that would facilitate BUP and ARV measurement from a single 3 mL blood sample (0.75 mL plasma required) in conjunction with a previously validated multiple ARV HPLC method. The method measures BUP and NBUP over the range from 0.25 to 50 ng/mL with mass spectrometry detection. Inter- and intra-assay variation was 相似文献
43.
Objectives
The aim of this work was to audit the extent to which routine HIV care in the UK conforms with British HIV Association (BHIVA) guidelines and specifically the proportion of patients starting highly active antiretroviral therapy (HAART) who achieve the outcome of virological suppression below 50 HIV‐1 RNA copies/mL within 6 months.Methods
A prospective cohort review of adults with HIV infection who started antiretroviral therapy (ART) for the first time between April and September 2006 was carried out using structured questionnaire forms.Results
A total of 1170 adults from 122 clinical sites participated in the review. Of these patients, 699 (59.7%) started ART at CD4 counts <200 cells/μL and 193 (16.5%) had not been tested for HIV drug resistance. Excluding patients with valid reasons for stopping short‐term ART, 795 (73.5%) of 1081 patients had an undetectable viral load (VL) at follow‐up. Detectable VL was strongly associated with pretreatment CD4 count below 50 cells/μL and pretreatment VL above 100 000 copies/mL, and was not associated with clinic location or case load. About a quarter of patients did not have a VL measurement during the first 6 weeks after starting ART.Conclusions
The majority of patients who initiated ART at sites participating in this UK national audit were managed within the BHIVA guidelines and achieved virological suppression below 50 copies/mL around 6 months after commencing treatment. Poor VL outcomes were associated with very low CD4 cell count and/or high VL at baseline but not with clinic case load or location. There is an urgent need to diagnose patients at an earlier stage of their HIV disease. 相似文献44.
BACKGROUND: Cardiac arrhythmias have been linked to treatment with methadone and levacetylmethadol. HIV-positive patients often have conditions that place them at risk for QT interval prolongation including HIV-associated dilated cardiomyopathy, coronary artery disease as a consequence of highly active antiretroviral (ARV) therapy-associated metabolic syndrome, and uncorrected electrolyte abnormalities. As of February 14, 2006, no cases of adverse events related to QT interval prolongation have been reported in patients receiving buprenorphine, an opioid partial agonist and the newest drug approved for the treatment of opioid dependence. OBJECTIVE: To evaluate the effects of buprenorphine/naloxone alone and in combination with 1 of 5 ARV agents (efavirenz, nelfinavir, delavirdine, ritonavir, lopinavir/ritonavir) on the QT interval. METHODS: This study was prospective, open-label, and within-subject in design, with subjects serving as their own controls. In 50 HIV-negative, opioid-dependent subjects, electrocardiogram recordings were obtained at baseline, after receiving buprenorphine/naloxone for 2 weeks, and then following buprenorphine/naloxone plus ARV administration for 5-15 days at steady-state. QTc interval measurements were compared using mixed-model, repeated-measures ANOVA. Recent cocaine use and gender were considered covariates. RESULTS: Buprenorphine/naloxone alone and often in the presence of evidence for recent use of cocaine did not significantly alter the QT interval (p = 0.612). Buprenorphine/naloxone in combination with ARVs caused a statistically, but not clinically, significant increase (p = 0.005) in the QT interval. Subjects receiving buprenorphine/naloxone in combination with either delavirdine or ritonavir had the greatest increase in QTc intervals. CONCLUSIONS: Prolonged QT intervals were not observed in opioid-dependent subjects receiving buprenorphine/naloxone alone. QT interval increases were observed with buprenorphine/naloxone in combination with either delavirdine or ritonavir, which inhibit CYP3A4. 相似文献
45.
46.
Providing effective medical care to those with substance use disorders can be a challenge to clinicians. In this article, we briefly summarize issues that occur frequently in the medical treatment of substance users. The focus of this article is twofold. The first is to briefly summarize common co-occurring medical illnesses in those manifesting substance use disorders with an emphasis on issues related to providing effective treatment for these diseases in this population. Using specific examples of frequently occurring comorbid medical illness in substance users, including infectious diseases (hepatitis C and HIV disease), sexually transmitted diseases, and pregnancy as examples, the complexities of medical care for this population is demonstrated. Second, this article addresses some of the difficulties encountered in pharmacotherapy aimed specifically at treatment of substance use disorders. For example, difficulties in managing concomitant opiate therapy in those requiring medications for medical illness that may have strong and adverse interactions with opiates are addressed. Adverse events reported for some substance use disorder pharmacotherapies are also highlighted. We conclude with a brief review of models of care that have been effective in addressing the needs of this challenging population that can provide additional means for enhancing the clinical care of substance users. 相似文献
47.
48.
Cooperative enhancement of F-cell formation in baboons treated with erythropoietin and hydroxyurea 总被引:2,自引:2,他引:0
Al-Khatti A; Papayannopoulou T; Knitter G; Fritsch EF; Stamatoyannopoulos G 《Blood》1988,72(2):817-819
Chronically anemic baboons on a continuous hydroxyurea regimen were treated with pulsed doses of recombinant human erythropoietin (rHuEpo) to test whether the combination of these two compounds, which individually induce F-cell production, can enhance further F-cell output. A low-F-cell-responding animal under chronic hydroxyurea treatment was given three separate pulses of Epo and responded with F- reticulocyte increments that were similar to the sum increments caused by either hydroxyurea alone or rHuEpo alone. The same results were obtained in a high-F-responding animal similarly treated. These findings suggest that rHuEpo and hydroxyurea can increase F cell numbers in an additive fashion. It is speculated that both compounds act through perturbation of erythroid differentiation kinetics. 相似文献
49.
Lack of a co-promoting effect of a 60 Hz magnetic field on skin tumorigenesis in SENCAR mice 总被引:4,自引:3,他引:1
Sasser LB; Anderson LE; Morris JE; Miller DL; Walborg EF Jr; Kavet R; Johnston DA; DiGiovanni J 《Carcinogenesis》1998,19(9):1617-1621
It has been proposed that extremely low frequency (ELF) magnetic fields may
enhance tumorigenesis through a co-promotional mechanism. This hypothesis
has been further tested using the two-stage model of mouse skin
carcinogenesis, i.e. 12-O-tetradecanoylphorbol-13-acetate (TPA)- induced
promotion of skin tumors in mice initiated by a single subcarcinogenic dose
of 7,12-dimethylbenz[a]anthracene. Experimentation described herein
utilized the SENCAR mouse and examined the effect of a magnetic field on
skin tumor promotion induced by three different doses of TPA within its
dose-response range, i.e. 0.85, 1.70 or 3.40 nmol, administered twice per
week. SENCAR mice (56/treatment group) were exposed to a 60 Hz magnetic
field having a flux density of 2 mT for 6 h/day for 5 days/week and
compared with mice exposed to the ambient magnetic field. Tumor incidence
and multiplicity were monitored weekly for 23 weeks of TPA promotion.
Statistical evaluation of the effects of the magnetic field on tumor
incidence and multiplicity did not reveal any statistically significant
effects; thus, within the sensitivity limits imposed by the animal model
and the exposure parameters employed, no promotional or co-promotional
effect of a 2 mT magnetic field on skin tumor development in SENCAR mice
could be demonstrated.
相似文献
50.
Increased colonic wall thickness has been reported in patients exposed to large doses of high strength pancreatic enzyme preparations who did not develop fibrosing colonopathy. This has been interpreted as evidence for a spectrum of subclinical disease. The relation between sonographically measured colonic wall thickness and pancreatic enzyme preparation and dose was studied in 86 children with cystic fibrosis (CF). Colonic wall thickness of a control group was also measured. The average thickness in all colonic regions was higher in the CF group (overall average range 0.7-2.5 mm v 0.6-1.4 mm in the control group). There was no significant relation between colonic wall thickness and age, sex, total dose of lipase, or copolymer. Apart from one patient with an early colonic stricture, none of those exposed to high doses of lipase, or the methacrylic acid copolymer Eudragit L30 D55, showed evidence of subclinical damage to the colon. The reproducibility of the sonographic measurements was poor. 相似文献